A hallmark observation in pancreatic cancer management is that neratinib reduces K-RAS hyperactivity, the common cancer mark, through inhibition of MST1/3/4 and Hippo signaling8; this makes neratinib a potent option for the therapy of the diabetes–pancreas cancer comorbidity. Here, MST1 is linked to diabetes mellitus.